Olainfarm
|
company logo | |
| Joint stock company | |
| Traded as | OMX: OLF1R |
| Industry | Pharmaceuticals |
| Predecessor | Olaine Chemical-Pharmaceutical Plant |
| Founded | 10 June 1991[1] |
| Headquarters | Olaine, Latvia |
Area served | Worldwide |
Key people | Valērijs Maligins (CEO) |
| Revenue | € 78 million (2013) |
 € 12.6 million (2013) | |
| Owner | Olmafarm (42.56%) Valērijs Maligins (26.22%) |
| Website | olainfarm.lv |
AS Olainfarm (OMX: OLF1R) is a Latvian company listed on the Riga OMX exchange with production of pharmaceutical drugs,chemical ingredients and active pharmaceutical ingredients. Products of JSC Olainfarm are exported to more than 35 countries, including the Baltic States, Russia, other CIS countries, Scandinavian, Western European and Asian countries, as well as North America and Australia.
The company was founded in 1972 as state enterprise “Olaines ķīmiski – farmaceitiskā rūpnīca” (Olaine Chemical-Pharmaceutical Plant). The main goal of founding the company was to ensure pharmaceutical substances and semiproducts to several finished drug form manufacturing plants in the Soviet Union. As a result of privatization in 1997, the Company was reorganized into a joint stock company and its shares were listed on stock exchange.
As of 2015, JSC Olainfarm is a large pharmaceutical company in Latvia and the Baltic states, with more than 1000 employees. The company owns the controlling stake in the leading Latvian food supplement company Silvanols, and has its own chain of pharmacies Latvijas aptieka in Latvia.
JSC Olainfarm is certified in accordance with the requirements of the EU GMP for APIs and FDFs, the U.S. cGMP for certain APIs (FDA), TGA for FDFs (Australia), ISO 14001 Environmental Management System and ISO 17025 Laboratory Management System.
JSC Olainfarm produces over 60 final dosage forms and 30 active pharmaceutical ingredients and intermediates. The product portfolio is well diversified with the main emphasis on branded products, historically unique to Olainfarm. The key areas of specialization in final dosage forms include neurology (cholinesterase inhibitors, anxiolytics, psychostimulants, nootropics), cardiology (antiarrhythmics, energy metabolism enhancers), infectology (original nitrofurantoine derivatives and antivirals) and allergology (fast acting antihistamines).
References
- ↑ "Joint Stock Company Olaine Annual Report 2009". nasdacomxbaltic.com. 2010-04-01. p. 5. Retrieved 2010-11-03.
| ||||||
